Candel Therapeutics Stock Fundamentals
| CADL Stock | USD 4.51 0.06 1.31% |
Candel Therapeutics fundamentals help investors to digest information that contributes to Candel Therapeutics' financial success or failures. It also enables traders to predict the movement of Candel Stock. The fundamental analysis module provides a way to measure Candel Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Candel Therapeutics stock.
At this time, Candel Therapeutics' Cost Of Revenue is quite stable compared to the past year. Total Operating Expenses is expected to rise to about 21.3 M this year, although the value of Interest Income will most likely fall to about 1.2 M. Candel | Select Account or Indicator |
Candel Therapeutics Company Shares Outstanding Analysis
Candel Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Candel Therapeutics Shares Outstanding | 32.48 M |
Most of Candel Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Candel Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Candel Shares Outstanding Historical Pattern
Today, most investors in Candel Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Candel Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Candel Therapeutics shares outstanding as a starting point in their analysis.
Candel Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Candel Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Candel Therapeutics has 32.48 M of shares currently outstending. This is 82.01% lower than that of the Biotechnology sector and 69.61% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 94.32% higher than that of the company.
Candel Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Candel Therapeutics's current stock value. Our valuation model uses many indicators to compare Candel Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Candel Therapeutics competition to find correlations between indicators driving Candel Therapeutics's intrinsic value. More Info.Candel Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Candel Therapeutics' Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Candel Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Candel Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Candel Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Candel Therapeutics could also be used in its relative valuation, which is a method of valuing Candel Therapeutics by comparing valuation metrics of similar companies.Candel Therapeutics is currently under evaluation in shares outstanding category among its peers.
Candel Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Candel Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Candel Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Candel Fundamentals
| Return On Equity | -4.81 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 147.88 M | ||||
| Shares Outstanding | 32.48 M | ||||
| Shares Owned By Insiders | 30.39 % | ||||
| Shares Owned By Institutions | 22.53 % | ||||
| Number Of Shares Shorted | 2.1 M | ||||
| Price To Book | 30.41 X | ||||
| Price To Sales | 436.42 X | ||||
| Revenue | 31 K | ||||
| Gross Profit | (20.66 M) | ||||
| EBITDA | (37.43 M) | ||||
| Net Income | (37.94 M) | ||||
| Cash And Equivalents | 86.78 M | ||||
| Cash Per Share | 3.00 X | ||||
| Total Debt | 22.76 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 14.86 X | ||||
| Book Value Per Share | 0.44 X | ||||
| Cash Flow From Operations | (34.24 M) | ||||
| Short Ratio | 7.72 X | ||||
| Earnings Per Share | (1.73) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 42 | ||||
| Beta | -0.87 | ||||
| Market Capitalization | 134.29 M | ||||
| Total Asset | 41.2 M | ||||
| Retained Earnings | (137.03 M) | ||||
| Working Capital | 22.61 M | ||||
| Net Asset | 41.2 M |
About Candel Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Candel Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Candel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Candel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 129.6 K | 123.1 K | |
| Total Revenue | 31 K | 29.4 K | |
| Cost Of Revenue | 24 M | 25.2 M | |
| Stock Based Compensation To Revenue | 16.61 | 12.44 | |
| Sales General And Administrative To Revenue | 101.23 | 51.95 | |
| Research And Ddevelopement To Revenue | 149.67 | 82.12 | |
| Capex To Revenue | 9.34 | 7.62 | |
| Ebit Per Revenue | (319.44) | (335.41) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Candel Therapeutics Piotroski F Score and Candel Therapeutics Altman Z Score analysis. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Revenue Per Share 0.001 | Return On Assets (0.52) | Return On Equity (4.81) |
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.